Day 3 Co conferences and Plenary April 12

Cancer & Immunotherapy
09:10

How to overcome tumour immunosuppression – Understanding immunosuppression in the microenvironment that leads to anti-tumour activity

  • Understanding the mechanism that is preventing T-cells from killing cancer cells
  • The important role tumor-induced T reg cells play and development of strategies to overcome this effect
  • Employing anti-CD4 antibody to partially deplete CD4 T-cells
  • Using this method in PhI clinical trials to uncover therapeutic efficacy in a multiple vaccination model
Influenza and Respiratory
09:10

Scientific challenges and results on developing a new pertussis vaccine

  • The need for a new pertussis vaccine with longer lasting immunity
  • Challenges in making an effective pertussis vaccines: Cyclical by nature, waning immunity, asymptomatic carriers
Emerging Diseases
09:10

Shigella vaccine built on GMMA technology – Using outer membrane particles shed from genetically engineered bacteria for cost effective vaccines

  • The potential impact and cost-effectiveness of a Shigella vaccine in developing countries
  • Potential of the GMMA technology in vaccine strategies targeting poverty related diseases
Veterinary
09:10

Developing vaccines to eradicate the FMD disease virus

 
  • Vaccination as an intervention strategy to support the global control and eradication of foot-and-mouth
  • Development of new process technology and improvement on product claims; new generation vaccines to overcome challenges in vaccine development associated with viral diversity, short immunity durations and temperature instability
  • Developments, opportunities and current challenges
Partnerships April 12
09:10

Developing new standards for building trust with pharmaceutical companies: A reflection on GlaxoSmithKline’s (GSK’s) journey

  • Changing the standard ways of working that industry uses with its academic and public health customers
  • How to become a trusted partner in the scientific and public health community to deliver the best quality of healthcare to patients
  • Changing the standard ways of working that industry uses with its academic and public health customers
  • How to become a trusted partner in the scientific and public health community to deliver the best quality of healthcare to patients
 
Influenza and Respiratory
09:40

Disease modifying vaccines in Chronic Obstructive Pulmonary Disease (COPD)

-          Presenting early stage development of a vaccine to prevent the bacterial infections that exacerbate COPD
-          COPD is a very common, chronic, progressive, respiratory illness of adults, which can be triggered by bacterial infections
-          A vaccine to prevent these respiratory infections could modify the clinical progression of COPD, and improve quality of life
Emerging Diseases
09:40

Interactive discussion: Using the recent license of Cholera vaccine as a case study

  • Single-dose live oral cholera vaccine shown to protect cholera in protection in a human cholera challenge model
  • Lessons learned from the regulatory approval that may be applicable to other vaccines
  • Next steps to have this available for children and for use outside of the US
Veterinary
09:40

New fragmentation and solubilization approaches toward bacterial and viral vaccines

  • A proprietary surfactant and detergent based approach consisting either on membrane splitting and/ or solubilization and stabilization
  • Presenting protection to commercialized influenza vaccines but using up to 30 times less antigens in one vaccine dose
  • Results from a bacterial vaccine against leptospirosis
Bioprocessing & Manufacture
09:40

Bioconjugation technology for the next generation of conjugate vaccines: Recent improvements, CQAs, and analytics method development

  • Technology advantages and opportunities
  • Focus on development and characterization of bioconjugate vaccine candidates
  • Discussion of CQAs based on preclinical and clinical POC data
Bioprocessing & Manufacture
09:40

Bioconjugation technology for the next generation of conjugate vaccines: Recent improvements, CQAs, and analytics method development

 
  • Technology advantages and opportunities
  • Focus on development and characterization of bioconjugate vaccine candidates
  • Discussion of CQAs based on preclinical and clinical POC data
Cancer & Immunotherapy
10:10

Can understanding antiviral immunity induced by oncolytic viruses predict their success as a tumor immunotherapy?

  • Oncolytic viruses as immunotherapy: progress and remaining challenges
  • How do we restrain antiviral immune responses and minimize pathology while promoting antitumor immunity to override immune tolerance?
  • Combining OV therapy with chemo- and immune-based therapeutic regimens and the risks
Influenza and Respiratory
10:10

The Multiple Antigen Presenting System: A platform for novel vaccines that elicit B- and Th1/Th17-cell responses

  • Are the current serotypes in the vaccine enough protection?
  • How can we measure and predict this?
  • Comparing cross protection with other vaccine candidates
Bioprocessing & Manufacture
10:10

Process Development, Scale-up and COG of conjugate vaccines

 
  • Presentation on Scale-up commercial manufacturing and challenges
  • Impact on COGS
  • Incl. Classical and modern  conjugation reactions
Partnerships April 12
10:10

Demonstrating the safety and efficacy profile of an alternative adjuvant delivery system against influenza

Dr Michael Vajdy, Co Founder, President and Chief Scientific Officer, Epito Genesis Inc
Emerging Diseases
10:25

Tools to assess and advance Group A Streptococcus Vaccines

 
  • Assembly and genome sequencing of a representative strain panel 
  • Economic analysis of vaccine implementation in Australia and New Zealand, compared to other public health initiatives
  • Development of a reference assay
  • A clinical development plan to move forward with
10:40

Networking coffee break

Cancer & Immunotherapy
11:30

Self-antigen T-cell vaccines for the treatment and prevention of breast and ovarian cancers

 
  • Integrating different cancer vaccine types and check point inhibitors in combinational approaches
  • Augmenting CD4 helper T-cell immunity using peptide epitopes
Influenza and Respiratory
11:30

NasoShieldTM anthrax vaccine candidate provides protection from challenge and rapid immunogenicity following a single intranasal dose

  • The currently licensed anthrax vaccine requires 3 administrations for protection
  • NasoShield demonstrates single dose protective efficacy in preclinical models of inhalation anthrax
  • Preclinically, the protective antibody response to NasoShield had faster onset and was more persistent than the licensed vaccine
  • A first in man, Phase 1 safety and immunogenicity study is planned for Q42017
Emerging Diseases
11:30

Paratyphoid A fever & vaccine development: The importance of vaccines with the rise of antibiotic resistance

 
  • Role of vaccines as a part of an integrated program to combat the spread of antibiotic resistance 
  • The need for a more effective Typhoid vaccine and an adequate supply needed to meet demand, particularly in the most affected countries
  • Overview of the promising candidates in the pipeline
Cancer & Immunotherapy
12:00

Comprehensive profiling of T cell responses to putative neoantigens reveals smarter targets for cancer immunotherapy

  • ATLAS™ is a clinically-proven platform that can comprehensively characterize the specificity and quality of HLA-diverse human T cell responses
  • T cell neoantigens identified using ATLAS are often missed by algorithms
  • Inhibitory neoantigens are emerging that could not be predicted in silico
  • ATLAS T cell profiles predict response to checkpoint blockade therapy
Influenza and Respiratory
12:00

Tuberculosis vaccine R&D: Addressing a global epidemic

 
  • New insights into why immunity from BCG vaccine is so variable
  • Paving the way we develop new TB vaccines
  • Identify immune correlates that could facilitate TB vaccine development
Emerging Diseases
12:00

Strategies for developing vaccines against ETEC

The need for an ETEC vaccine and the current landscape of candidates  will be reviewed.  This will be followed by an in depth analysis of the most advanced of these candidates, ETVAX, an inactivated whole cell vaccine which PATH is developing in collaboration with Scandinavian BioPharma. This product exceeded its primary endpoints in a phase 1 trial in Finnish volunteers and is currently being evaluated in a descending age study in Bangladesh.  It is being administered with and without the mucosal adjuvant dmLT.  It may in the future be combined with a vaccine candidate for Shigella.
Veterinary
12:00

Eradicating Porcine Cysticercosis with a novel vaccine containing the TSol 18 protein

 
  • Global clinical trials demonstrating the efficacy of the vaccine in protecting pigs against T.solium
  • Recombinant vaccine containing TSol 18 protein licensed for commercial use for first time in the world
  • Exciting eradication potential and lessons learnt from development challenges faced
12:30

Networking Lunch & Poster Session

Dr Gregory A. Poland
Partnerships April 12
13:30

UBER Vaccinology:  A new operational and funding paradigm for vaccine innovation

  • Publically funded, not-for-profit model to de-risk vaccine development to meet public health needs and industry thresholds
  • Effective leveraging of funding through networks and partnerships
  • Fostering partnerships to drive vaccine innovation
  • Attaining self-sustainability in a not-for-profit organization
 
Dr Alan R. Hinman
13:40

The eradication of Polio: Have we succeeded?


-    Measuring and monitoring the success of eradication
-    End game and strategic plan
-    What’s next? Can we eradicate measles?
 
Professor Robert Daum
14:10

A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria


-    Recommendations from the National Vaccine Advisory Committee
-    Use of vaccines to prevent the infections that could or have developed AMR to antibiotics, in adjunction to antibiotic stewardship
-    Examples in Haemophilus influenza, Streptococcus, Staphylococcus aureus

 
Partnerships April 12
14:30

Support mechanisms to develop vaccines with better effectiveness: Why does the effectiveness of the rotavirus vaccine drop in middle to low income countries?

 
  • What vaccines are the NIH prioritizing and why?
  • How could we increase the efficacy of existing vaccines and why does it drop in low to middle income countries?
  • How to access government funding for vaccine development programs
Dr Gregory A. Poland
14:40

Panel: How much efficacy is enough? What are the implications of a vaccine no longer being a replacement technology but a companion technology?


-    The concept of partially protected vaccines like malaria, TB, NTDs where the clinical efficacy is no longer 85/90% but closer to 40% 
-    Future of vaccine development 
-    The combining drivers of technology and emerging diseases

More panelists to be announced shortly
Partnerships April 12
15:00

Addressing the fragmented landscape of funding opportunities for companies and academic developers of vaccines

  • How can different funders and vaccine developers work together to improve the environment of vaccine development
  • Setting global priorities for vaccine development
15:30

Chair’s closing remarks and close of congress

last published: 23/Feb/17 09:38 GMT